Akebia Therapeutics, Inc. - 8-K Filing

Akebia Therapeutics enters $140 million senior secured term loan facility with Symbiotic Capital and repays prior Kreos debt. (Items: 1.01 Entry into a Material Definitive AgreementEntry into Symbiotic Term Loan Facility On November 12, 2026 (the “Closing Date”), Akebia Therapeut, 1.02 below), including payment of certain customary termination fees and other expenses incurred in connection therewith, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a RegistrantThe information set forth un, 3.02 Unregistered Sales of Equity SecuritiesThe information set forth under Item 1)

SEC EDGAR ·

Tickers: $AKBA

Read the full article at SEC EDGAR

More Regulatory news